Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOPE2: Radiotherapy Dose Escalation and Chemo Switch in Oesophageal Cancer
NCT02741856Phase 3Unknown
- Start
- Nov 2016
- Primary completion
- Apr 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carboplatin and paclitaxel in esophageal cancer (4 arms). Primary endpoints: Treatment Failure Free Survival at 24 weeks and Overall Survival at 5 years. Status: unknown.
02
Drugs
carboplatinpaclitaxel
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02741856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02741856.